U.S. Markets open in 4 hrs 23 mins

SPDR S&P Biotech ETF (XBI)

NYSEArca - NYSEArca Delayed Price. Currency in USD
Add to watchlist
85.17+1.48 (+1.77%)
At close: 4:00PM EDT

85.28 +0.11 (0.13%)
Pre-Market: 4:28AM EDT

People also watch
Full screen
Previous Close83.69
Bid84.80 x 300
Ask0.00 x 0
Day's Range83.86 - 85.23
52 Week Range53.15 - 85.23
Avg. Volume3,997,110
Net Assets4.15B
PE Ratio (TTM)N/A
YTD Return41.89%
Beta (3y)1.69
Expense Ratio (net)0.35%
Inception Date2006-01-31
Trade prices are not sourced from all markets
  • Market Realist3 days ago

    Benefitting from IBB’s Lower Expense Ratio

    The iShares NASDAQ Biotechnology ETF (IBB) is an open-end fund with assets under management of $9.85 billion.

  • Barrons.com6 days ago

    The Biotech Rally Isn't Over Yet

    Biotech has been on a tear recently, and Barclays’ Paul Choi and Geoff Meacham write that investor will probably stay positive on the sector. They attribute the recent rally to the expectation that more ...

  • Barrons.com6 days ago

    RBC Launches Biotech Sector Coverage Amid 'An Innovation Revolution'

    RBC Capital Markets just launched coverage of the biotech sector, covered by Brian Abrahams, Kennen MacKay, and Matthew Eckler, and they spoke with Barrons.com about the industry, which they say is seeing a number of exciting innovations as we enter a new era of personalized medicine. Of course, biotech has been on a wild ride in recent years, but after being shunned by a number of investors previously, the sector is seeing new life in 2017, with the Nasdaq Biotechnology Index (NBI) up more than 25% this year, and SPDR S&P Biotech ETF (XBI) up more than 40%.